Dagostino Concetta, Allegri Massimo, Napolioni Valerio, D'Agnelli Simona, Bignami Elena, Mutti Antonio, van Schaik Ron Hn
Department of Medicine and Surgery, University of Parma, Parma 43126, Italy,
Study In Multidisciplinary Pain Research (SIMPAR), Milan 20100, Italy,
Pharmgenomics Pers Med. 2018 Oct 24;11:179-191. doi: 10.2147/PGPM.S181334. eCollection 2018.
Opioids are widely used for chronic low back pain (CLBP); however, it is still unclear how to predict their effectiveness and safety. Codeine, tramadol and oxycodone are metabolized by CYP/CYP450 2D6 (CYP2D6), a highly polymorphic enzyme linked to allele-specific related differences in metabolic activity.
genetic polymorphisms could potentially help to predict the effectiveness and safety of opioid-based drugs in clinical practice, especially in the treatment of CLBP.
A cohort of 224 Italian patients with CLBP treated with codeine or oxycodone was retrospectively evaluated to determine whether adverse reactions and effectiveness were related to single-nucleotide polymorphisms. genotyping was performed using the xTAG CYP2D6 Kit v3 (Luminex) to determine metabolizer phenotype (poor, intermediate, rapid and ultrarapid). Subjects from the cohort were categorized into two groups according to the occurrence of side effects (Case) or benefit (Control) after chronic analgesic treatment. The impact of polymorphism on treatment outcome was tested at the metabolizer phenotype, diplotype and haplotype levels.
polymorphism was significantly associated with opioid treatment outcome (Omnibus =0.018, for both global haplotype and diplotype distribution test). *6 and *9 carriers, alleles characterized by a reduced (*9) or absent (*6) enzymatic activity, were significantly (<0.05) associated with therapeutic failure. ultrarapid metabolizers (*2N patients) showed an increased risk of side effects, as would be predicted. Despite their low frequency, *1/*11, *4/*6 and 41/ 2N diplotypes showed significant (<0.05) associations of efficacy and side effects with chronic opioid treatment.
Our results showed that reduced CYP2D6 activity is correlated with lack of therapeutic effect. We found that the pharmacogenetic analysis of could be helpful in foreseeing the safety and effectiveness of codeine or oxycodone treatment in CLBP.
阿片类药物广泛用于慢性下腰痛(CLBP)的治疗;然而,如何预测其有效性和安全性仍不清楚。可待因、曲马多和羟考酮由细胞色素P450 2D6(CYP2D6)代谢,CYP2D6是一种高度多态性的酶,与代谢活性中特定等位基因相关差异有关。
基因多态性可能有助于预测阿片类药物在临床实践中的有效性和安全性,尤其是在CLBP治疗中。
对224例接受可待因或羟考酮治疗的意大利CLBP患者进行回顾性评估,以确定不良反应和有效性是否与单核苷酸多态性相关。使用xTAG CYP2D6试剂盒v3(Luminex)进行基因分型,以确定代谢表型(慢代谢、中间代谢、快代谢和超快代谢)。根据慢性镇痛治疗后副作用(病例组)或获益(对照组)的发生情况,将队列中的受试者分为两组。在代谢表型、双倍型和单倍型水平上测试多态性对治疗结果的影响。
多态性与阿片类药物治疗结果显著相关(全局单倍型和双倍型分布检验的综合P值均为0.018)。6和9携带者,其等位基因的酶活性降低(*9)或缺失(*6),与治疗失败显著相关(P<0.05)。超快代谢者(2N患者)出现副作用的风险增加,正如预期的那样。尽管频率较低,但1/*11、*4/6和41/*2N双倍型显示出与慢性阿片类药物治疗的疗效和副作用显著相关(P<0.05)。
我们的结果表明,CYP2D6活性降低与治疗效果不佳相关。我们发现,对CYP2D6进行药物遗传学分析有助于预测可待因或羟考酮治疗CLBP的安全性和有效性。